HCPCS code J3473 – Recombinant hyaluronidase injection

Key takeaways

HCPCS code J3473 reports injection of recombinant hyaluronidase, such as Hylenex recombinant, at one billing unit per 1 USP unit given.

Ovine preservative-free hyaluronidase, such as Vitrase, is billed with J3471 or J3472, and J3470 covers hyaluronidase up to 150 units.

A fully used 150 USP unit vial goes on the claim as 150 units. The JW or JZ modifier shows whether any drug was discarded.

The NDC goes in the shaded area of item 24A on the CMS-1500, or loop 2410 on an 837P, with the N4 qualifier.

Pabau, the practice software we build, keeps the product, dose and NDC on the treatment record, so each J3473 claim line matches the chart.

HCPCS code J3473: Official descriptor and drug overview

HCPCS code J3473 is the Level II code for injection, hyaluronidase, recombinant, 1 USP unit.

It reports a physician-administered dose of recombinant human hyaluronidase, sold in the US as Hylenex recombinant. Each billing unit equals 1 USP unit of drug.

Hyaluronidase is an enzyme that temporarily breaks down hyaluronic acid in connective tissue. That makes the tissue more permeable, so fluids or injected drugs spread and absorb faster. The recombinant form is made by recombinant DNA technology, so it carries no animal source.

The code sits in the J0013-J8999 range of HCPCS Level II, which covers drugs administered other than by mouth. J3473 has been part of the code set for many years, so the coding question is rarely whether it exists. The question is whether the product in the vial was recombinant hyaluronidase. The neighboring drug codes, including the other hyaluronidase codes, are in our HCPCS code library.

What J3473 covers and what it excludes

J3473 covers physician-administered injections of recombinant hyaluronidase. The drug source is what decides the code, so the chart has to name the product given.

Covered under J3473:

• Recombinant human hyaluronidase, such as Hylenex recombinant, given by a physician or by clinical staff under physician supervision
• Use as an adjuvant in subcutaneous fluid administration for hydration (hypodermoclysis)
• Use to increase the dispersion and absorption of other injected drugs
• Use in subcutaneous urography to improve resorption of radiopaque agents

Excluded from J3473:

• Ovine hyaluronidase, preservative free, such as Vitrase, which is billed with J3471 or J3472
• Bovine hyaluronidase products, which are billed with J3470 (injection, hyaluronidase, up to 150 units)
• Patient self-administration, because J-codes report drugs given in a clinical setting

Billing an ovine product? If your practice stocks Vitrase or another ovine, preservative-free hyaluronidase, J3473 is the wrong code. Use J3471 for injection, hyaluronidase, ovine, preservative free, per 1 USP unit (up to 999 USP units). Use J3472 for the same drug per 1,000 USP units.

Clinical uses: When is recombinant hyaluronidase given?

Recombinant hyaluronidase is given to help other fluids or drugs spread through tissue. Coders need the clinical context because the indication has to be documented to support a J3473 claim. The labeled uses for Hylenex recombinant are:

• Hypodermoclysis: Subcutaneous fluid administration for hydration, often in older or palliative patients where IV access is difficult
• Drug dispersion: Given with another injected drug to increase its dispersion and absorption
• Subcutaneous urography: Used to improve resorption of radiopaque contrast agents

Aesthetic practices also use hyaluronidase to dissolve hyaluronic acid filler. That use is off-label. A purely cosmetic correction is generally not covered by Medicare or commercial plans, so the patient usually pays for it directly. When the injection treats a filler complication, coverage depends on the payer and the documented diagnosis.

The administering provider and the clinical indication must both appear in the encounter note. Vague indication language leads to medical necessity denials for this code.

J3473 vs J3470, J3471 and J3472: Choosing the right hyaluronidase code

Four HCPCS codes describe hyaluronidase, and the product source decides which one applies. J3473 is the only one for the recombinant form.

The deciding fact is the product name on the administration record. If the chart only says “hyaluronidase,” the coder cannot pick between these codes safely. Query the clinician or check the stock record before the claim goes out. A bovine product such as Amphadase belongs on J3470, where one unit covers up to 150 units of drug.

How to bill HCPCS code J3473: Units, modifiers and claim submission

A J3473 claim line needs three facts right: the USP units given, the NDC of the vial used, and the place of service. The worked example below shows where each one sits on a CMS-1500 service line. Good claims management software captures them at the point of care, which cuts the manual re-entry behind unit errors.

Step-by-step billing workflow

1. Verify the product: Confirm the chart names recombinant hyaluronidase, such as Hylenex recombinant. If the product was ovine or bovine, switch to J3471, J3472 or J3470.
2. Calculate units: Report one unit of J3473 for each USP unit given. A dose of 150 USP units goes on the claim as 150 units.
3. Report discarded drug: Hylenex comes in single-dose vials, so Medicare Part B expects the JW or JZ modifier. Append JZ when none of the vial was wasted.
4. Attach the NDC: Enter the N4 qualifier, the 11-digit NDC, the unit of measure and the quantity for the vial used.
5. Select the place of service: Use 11 for a physician office, or the code that matches the setting where the drug was given.
6. Add the administration code: Report the CPT administration service separately where payer rules allow it (see the next section). For a pump infusion, 96370 and 96371 are add-on codes reported only with 96369.
7. Run a final check: Confirm a supporting diagnosis, a complete NDC line and no missing fields. The claim then goes out as a clean claim.

Unit calculation examples

Document the discarded amount in the record whenever you bill a JW line. Medicare can recoup wastage that the chart does not show.

Companion CPT administration codes for J3473

J3473 covers only the drug. The administration service is reported with a CPT code, and the right one depends on how the drug was given. 96369 covers pump-based subcutaneous infusion of a drug, and 96370 and 96371 are add-on codes reported only with it.

When hyaluronidase is mixed with another drug in the same injection, a second administration code usually is not reported. Check NCCI edits and your payer policy before you add one.

NDC reporting requirements for J3473

Medicaid programs require the NDC on physician-administered drug claims, and many Medicare contractors and commercial payers ask for it too. For J3473, the NDC must match the recombinant hyaluronidase product actually given.

On the paper CMS-1500, the NDC goes in the shaded area of item 24A, above the service line. On an 837P electronic claim, it goes in loop 2410. The format is the N4 qualifier, the 11-digit NDC, a unit qualifier such as ML or UN, and the quantity.

The NDC quantity uses the package unit of measure, so it rarely equals the HCPCS unit count. Check the NDC against the current CMS NDC-HCPCS crosswalk before submission, because an outdated NDC triggers a rejection.

Documentation requirements for J3473 claims

Strong medical billing compliance starts with what the clinician documents at the point of care. The medical record must contain the following to support a J3473 claim:

• Drug name and source: The product name, such as Hylenex recombinant, so the coder can tell it apart from ovine or bovine hyaluronidase
• Dose in USP units: The exact USP units given, plus any amount discarded from the vial
• Route of administration: Subcutaneous injection or infusion, stated explicitly
• Clinical indication: Why the drug was needed, including the diagnosis or the drug it was helping to disperse
• Administering provider: The name and role of the person who gave the drug, to support incident-to rules where they apply
• NDC of the vial used: Recorded when the vial is opened

Some Medicare Administrative Contractors publish Local Coverage Determinations or billing articles with extra conditions. Check your MAC’s guidance before billing.

Medicare Part B coverage and reimbursement for J3473

Medicare Part B covers J3473 as a physician-administered drug when medical necessity is documented. Payment follows the Average Sales Price method, at ASP plus 6% in the physician office setting, and CMS updates the rate every quarter.

The current payment limit for J3473 is published in the CMS Physician Fee Schedule and ASP drug pricing files. Never reuse a prior quarter’s rate, because ASP changes with manufacturer-reported sales data. A rate hardcoded into a fee schedule can leave your practice collecting less than it should.

For US practices, Pabau sends claims through the Claim.MD clearinghouse to thousands of US payers and checks eligibility before treatment. Reading the electronic remittance advice for each J3473 claim helps you spot underpayments early.

Prior authorization requirements

Original Medicare does not generally require prior authorization for a Part B drug like J3473. Medicare Advantage and commercial plans set their own rules, so check each payer before the drug is given.

When prior authorization is required, include the clinical indication, the product NDC, the expected dose in USP units and the ordering physician. A denial at the authorization stage is easier to fix than a post-service claim denial.

Common reasons HCPCS code J3473 claims are denied

J3473 denials tend to follow a few predictable errors. Strong denial management workflows catch each one before submission.

The CARC on the remittance tells you why a claim was denied. CO-4 means the modifier is wrong or missing, and CO-16 means information is missing, such as the NDC. CO-50 means the payer does not consider the service medically necessary. Appeal with the administration record, the NDC and the indication note attached.

How Pabau keeps J3473 claims complete before submission

Practices billing J3473 often find the drug details scattered. The product name sits in one note, the dose in another, and the NDC on a box in the stock room. Pabau brings them into one treatment record that your billing team works from.

• Structured treatment records: Clinicians log the product, USP dose, route, wasted amount and vial NDC in the encounter. The biller never has to chase the chart.
• Claim preparation: Pabau builds the electronic CMS-1500 claim from the invoice, which cuts the re-keying that causes unit errors.
• Eligibility and remittance: Through Claim.MD, US practices check coverage before the visit and match each payment back to its claim.

The result is a J3473 claim line that matches the chart, the vial and the payer rules before it leaves your practice.

Send J3473 claims out complete the first time

Pabau keeps the hyaluronidase product, USP dose and NDC on the treatment record. Your billing team then builds each J3473 line from the chart.

Book a demo

Conclusion

J3473 is a narrow code, and the product name decides it. If the vial was Hylenex recombinant, bill J3473 at one unit per USP unit, with JW or JZ and the NDC in item 24A. If it was Vitrase, move to J3471 or J3472.

Fix the record before you fix the claim. A chart that names the product, the dose and the discarded amount makes the code choice obvious and the appeal rare. Book a demo to see how Pabau carries physician-administered drug details from the treatment note to a paid claim.

Continue your research

Need to understand how claim denials are managed at scale? Denial management in healthcare covers root cause analysis, CARC code interpretation, and workflow fixes for recurring rejection patterns.

Want to understand what makes a claim pass on first submission? Clean claim submission explains the data completeness and edit checks that separate a paid claim from a pended one.

Looking for the broader context of J-code billing? Medical billing workflows walks through the full revenue cycle from encounter to payment, including physician-administered drug claims.

Billing Vitrase in larger doses? HCPCS code J3472 covers ovine, preservative-free hyaluronidase billed per 1,000 USP units.

Frequently asked questions